TOLVAPTAN and POLYURIA

Overview

POLYURIA is the #12 most commonly reported adverse reaction for TOLVAPTAN, manufactured by Otsuka America Pharmaceutical, Inc.. There are 419 FDA adverse event reports linking TOLVAPTAN to POLYURIA. This represents approximately 1.7% of all 24,584 adverse event reports for this drug.

Patients taking TOLVAPTAN who experience polyuria should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

POLYURIA is a less commonly reported adverse event for TOLVAPTAN, but still significant enough to appear in the safety profile.

Other Side Effects of TOLVAPTAN

In addition to polyuria, the following adverse reactions have been reported for TOLVAPTAN:

• DEATH — 973 reports
• OFF LABEL USE — 814 reports
• RENAL IMPAIRMENT — 804 reports
• CARDIAC FAILURE — 785 reports
• THIRST — 775 reports
• PRODUCT DOSE OMISSION ISSUE — 522 reports
• PRODUCT USE IN UNAPPROVED INDICATION — 487 reports
• WRONG TECHNIQUE IN PRODUCT USAGE PROCESS — 480 reports
• UNDERDOSE — 477 reports
• DEHYDRATION — 449 reports

Other Drugs Associated with POLYURIA

The following drugs have also been linked to polyuria in FDA adverse event reports:

Does TOLVAPTAN cause POLYURIA?

POLYURIA has been reported as an adverse event in 419 FDA reports for TOLVAPTAN. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is POLYURIA with TOLVAPTAN?

POLYURIA accounts for approximately 1.7% of all adverse event reports for TOLVAPTAN, making it a notable side effect.

What should I do if I experience POLYURIA while taking TOLVAPTAN?

If you experience polyuria while taking TOLVAPTAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages